Nautilus Biotechnology, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| NAUT | SEER | 1873.HK | TECH | DNA | PRTA | |
|---|---|---|---|---|---|---|
| Market cap | 291.68M | 94.13M | 2.80B | 11.42B | 784.51M | 430.72M |
| P/E (TTM) | — | — | 16.9 | 62.7 | — | — |
| Forward P/E | -3.1 | -1.6 | 6.2 | 31.5 | -4.0 | -6.4 |
| Price/book | 2.5 | 0.4 | 0.6 | 5.4 | 1.8 | 1.5 |
| Dividend yield | — | — | — | 0.44% | — | — |
| 1-year change | +51.66% | −20.28% | −43.17% | +25.01% | +3.10% | −16.77% |
| Today | −2.55% | −1.73% | +5.04% | +0.10% | +8.27% | +2.19% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All NAUT news ›Nautilus Biotechnology: Bullish On Voyager's Upcoming Launch
Explore why Nautilus could be a long-term proteomics stock, with oncology expansion, research collaborations, and runway to launch Voyager. - NAUT is extending Voyager from tau into oncology, which I think will give it more applications…
Nautilus Biotechnolgy (NAUT) Receives a Buy from Guggenheim
Guggenheim analyst reiterated a Buy rating on Nautilus Biotechnolgy yesterday and set a price target of $4.00. The company’s shares closed yest... Guggenheim analyst reiterated a Buy rating on Nautilus Biotechnolgy yesterday and set a…
Core Laboratories GAAP EPS of $0.12 misses by $0.03, revenue of $132.1M in-line
Core Laboratories Q3 earnings: EPS missed and revenue was flat year over year. - Core Laboratories press release (CLB): Q3 GAAP EPS of $0.12 misses by $0.03. More on Core Laboratories
Nautilus Biotechnology GAAP EPS of -$0.12 beats by $0.02, revenue of $0.23M beats by $0.02M
Nautilus Biotechnology Q3 earnings beat estimates on EPS and revenue. - Nautilus Biotechnology press release (NAUT): Q3 GAAP EPS of -$0.12 beats by $0.02. - Revenue was $0.2 million for the third quarter of 2026, primarily driven by grant…
Leerink Partners Initiates Coverage on Nautilus Biotechnolgy With Outperform Rating, $4 Price Target
... Biotechnology & Medical Research Leerink Partners Initiates Coverage on Nautilus Biotechnolgy With Outperform Rating, $4 Price Target Published on 09/09/2026 at 07:47 am EDT
Nuvation Bio (NUVB) Expected to Release Quarterly Earnings on Wednesday
Posted by Sarita Garza on Oct 28th, 2026 Shares of NYSE:NUVB opened at $4.54 on Wednesday. The stock has a market capitalization of $1.59 billion, a price-to-earnings ratio of -10.31 and a beta of 1.61. The stock’s 50-day simple moving…
NCR Voyix to Release Third Quarter Earnings Results
Edible Garden Announces Commercial Supply Agreement and Strategic Partnership with Caney Fork Farms NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in…
Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026
The Manila Times Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026 SEATTLE, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilu
Nautilus Biotechnology, Inc. (NAUT) Q3 2026 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NAUT) Q3 2026 Earnings Call October 27, 2026 8:30 AM EDT Sujal Patel - Co-Founder, CEO, President, Secretary & DirectorAnna Mowry - CFO & TreasurerParag Mallick - Co-Founder, Chief Scientist & Director…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- seekingalpha.com4
- stocktitan.net2
- defenseworld.net1
- investingnews.com1
- manilatimes.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 13 articles, not a forecast.